<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51887">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01822730</url>
  </required_header>
  <id_info>
    <org_study_id>100000-068943</org_study_id>
    <nct_id>NCT01822730</nct_id>
  </id_info>
  <brief_title>A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis</brief_title>
  <official_title>A Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Hao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <authority>China: National Natural Science Foundation</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or
      environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical
      presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms),
      response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central
      dopaminergic neurotransmission) of both conditions. Both paliperidone and risperidone are
      second generation antipsychoticsï¼Œbut have same pharmacological effects of antipsychotic
      treatment and paliperidone may have more efficacy and safty.This study was designed to
      examine the acute efficacy, safety, and tolerability of paliperidone and risperidone for
      patients with MAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:A Multiple-Center, Randomized, Double-Blind.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The severity of psychosis</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital stay</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Positive and Negative Syndrome Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical general status</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital stay</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical general rating scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>paliperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>.Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone</intervention_name>
    <description>Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks</description>
    <arm_group_label>paliperidone</arm_group_label>
    <other_name>Paliperidone Extended-Release Tablets</other_name>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks</description>
    <arm_group_label>.Risperidone</arm_group_label>
    <other_name>Risperdal H20070057</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)
             criteria for Methamphetamine-Associated Psychosis.

          2. Must sign a Information consent form.

          3. Required to provide detailed address and phone number

        Exclusion Criteria:

          1. Serious organic disease.

          2. Suicide ideation or hurt others.

          3. Taking antipsychotic within two weeks before.

          4. drug allergy to  Risperidone or paliperidone.

          5. pregnancy and breastfeeding women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Hao, MD., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Wang, doctor</last_name>
    <phone>18684667092</phone>
    <email>visa8752@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Wang, doctor</last_name>
      <phone>18684667092</phone>
      <email>visa8752@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Gang Wang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 28, 2013</lastchanged_date>
  <firstreceived_date>March 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Wei Hao</investigator_full_name>
    <investigator_title>The Second Xiangya Hospital of Cental South University</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine-Associated Psychosis</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Risperidone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>9-hydroxy-risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
